INVO Bioscience, a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility, has amended its loan agreement with Decathlon Alpha V LP. The amendment is anticipated to provide the company with additional financial flexibility and capital to further its strategic growth initiatives. This report may be significant to those in the UK seeking fertility treatments, as INVO Bioscience’s efforts to make such treatments more affordable could potentially affect the cost of procedures like IVF, ICSI, and IUI in the UK.